Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chimeric antigen receptor T-cell therapy in secondary central nervous system lymphoma: A multicenter analysis.
Alsouqi A, Ahmed G, Wang J, Cassanello G, Szabo A, Rojek AE, Riedell PA, Awan F, Samples L, Shadman M, Hu M, Bachanova V, Wesson W, Ahmed N, Iqbal M, Kharfan-Dabaja MA, Scordo M, Johnson PC, Chen YB, Ito S, Hamadani M, Frigault M. Alsouqi A, et al. Among authors: shadman m. Am J Hematol. 2024 May 20. doi: 10.1002/ajh.27354. Online ahead of print. Am J Hematol. 2024. PMID: 38769663 No abstract available.
Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis.
Wang TP, Ahn KW, Shadman M, Kaur M, Ahmed N, Bacher U, Cerny J, Chen A, Epperla N, Frigault M, Grover N, Haverkos B, Hill B, Hossain N, Iqbal M, Jain T, Krem MM, Maakaron J, Modi D, Alhaj Moustafa M, Riedell P, Savani B, Sica RA, Sureda A, Wudhikarn K, Herrera AF, Sauter C, Hamadani M, Jimenez Jimenez A. Wang TP, et al. Among authors: shadman m. Leukemia. 2024 May 15. doi: 10.1038/s41375-024-02242-6. Online ahead of print. Leukemia. 2024. PMID: 38750138
Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison.
Shadman M, Tedeschi A, Mohseninejad L, Yang K, Lamanna N, Xu S, Cohen A, Challagulla S, Xue M, Williams R, O'Brien SM, Brown JR, Tam C. Shadman M, et al. Blood Cancer J. 2024 May 2;14(1):77. doi: 10.1038/s41408-024-01044-4. Blood Cancer J. 2024. PMID: 38697986 Free PMC article. No abstract available.
Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity.
Locke FL, Siddiqi T, Jacobson CA, Ghobadi A, Ahmed S, Miklos DB, Perales MA, Munoz J, Fingrut WB, Pennisi M, Gauthier J, Shadman M, Gowda L, Mirza AS, Abid MB, Hong S, Majhail NS, Kharfan-Dabaja MA, Khurana A, Badar T, Lin Y, Bennani NN, Herr MM, Hu ZH, Wang H, Baer A, Baro E, Miao H, Spooner C, Xu H, Pasquini MC. Locke FL, et al. Among authors: shadman m. Blood. 2024 Apr 18:blood.2023023447. doi: 10.1182/blood.2023023447. Online ahead of print. Blood. 2024. PMID: 38635762
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.
Kittai AS, Bond D, Huang Y, Bhat SA, Blyth E, Byrd JC, Chavez JC, Davids MS, Dela Cruz JP, Dowling MR, Duffy C, Ho C, Jacobson C, Jaglowski S, Jain N, Lin KH, Miller C, McCarthy C, Omer Z, Parry E, Rai M, Rogers KA, Saha A, Schachter L, Scott H, Senapati J, Shadman M, Siddiqi T, Stephens DM, Vanguru V, Wierda W, Woyach JA, Thompson PA. Kittai AS, et al. Among authors: shadman m. J Clin Oncol. 2024 Mar 29:JCO2400033. doi: 10.1200/JCO.24.00033. Online ahead of print. J Clin Oncol. 2024. PMID: 38552193
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study.
Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, Matasar MJ, Bosch F, Kim WS, Nastoupil LJ, Flinn IW, Shadman M, Diefenbach C, Cheah CY, Ma CY, Huang H, Kwan A, Wei MC, Yin S, Bartlett NL. Budde LE, et al. Among authors: shadman m. J Clin Oncol. 2024 Mar 28:JCO2302329. doi: 10.1200/JCO.23.02329. Online ahead of print. J Clin Oncol. 2024. PMID: 38547425
Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis of a large clinical trial safety database.
Brown JR, Ghia P, Jurczak W, Kahl BS, Lamanna N, Robak T, Shadman M, Tam CS, Qiu L, Paik J, Salmi T, Wang L, Zhang J, Zhang M, Cohen A, Ma H, Tedeschi A. Brown JR, et al. Among authors: shadman m. Haematologica. 2024 Feb 29. doi: 10.3324/haematol.2023.283846. Online ahead of print. Haematologica. 2024. PMID: 38426293 Free article. No abstract available.
Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study.
Samples L, Voutsinas J, Fakhri B, Khajavian S, Spurgeon S, Stephens D, Skarbnik A, Mato A, Broome C, Gopal A, Smith S, Lynch R, Rainey M, Kim MS, Barrett-Campbell O, Hemond E, Tsang M, Ermann D, Malakhov N, Rao D, Shakib-Azar M, Morrigan B, Chauhan A, Plate T, Gooley T, Ryan K, Lansigan F, Hill B, Pongas G, Parikh SA, Roeker L, Allan JN, Cheng R, Ujjani C, Shadman M. Samples L, et al. Among authors: shadman m. Blood Adv. 2024 May 14;8(9):2085-2093. doi: 10.1182/bloodadvances.2023011569. Blood Adv. 2024. PMID: 38315043 Free PMC article.
159 results